All In Biotech

Drug Trial Radar · NCT05321498

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2023

Primary completion

Oct 26, 2023

Study completion Oct 26, 2023

Sponsor

Lead sponsor
Inmune Bio, Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with neuroinflammation (APOE4) and to evaluate safety, tolerability, and efficacy of XPro1595.

Conditions

  • Mild Cognitive Impairment (MCI)
  • Alzheimer Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Mental Disorders

Interventions

  • XPro1595Drug

    XPro1595 will be delivered by subcutaneous injection once a week.

  • PlaceboDrug

    Placebo will be delivered by subcutaneous injection once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)Time frame: 12 Weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.